TI
DNLI icon

Trexquant Investment’s Denali Therapeutics DNLI Stock Holding History

Trexquant Investment’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-209,609
Closed -$3.46M – 1823
2025
Q4 		$3.46M Sell
209,609
-220,957
-51% -$3.73M 0.03% 760
2025
Q3 		$6.25M Buy
430,566
+321,324
+294% +$4.62M 0.06% 457
2025
Q2 		$1.53M Sell
109,242
-3,982
-4% -$56K 0.02% 981
2025
Q1 		$1.54M Buy
113,224
+52,568
+87% +$1.01M 0.02% 951
2024
Q4 		$1.24M Buy
60,656
+36,122
+147% +$925K 0.01% 1028
2024
Q3 		$715K Buy
+24,534
New +$608K 0.01% 1158
2023
Q4 		– Sell
-42,349
Closed -$874K – 1509
2023
Q3 		$874K Sell
42,349
-24,586
-37% -$624K 0.02% 801
2023
Q2 		$1.98M Sell
66,935
-13,589
-17% -$382K 0.05% 496
2023
Q1 		$1.86M Buy
80,524
+57,669
+252% +$1.59M 0.05% 484
2022
Q4 		$636K Sell
22,855
-2,774
-11% -$82.5K 0.02% 818
2022
Q3 		$787K Buy
+25,629
New +$833K 0.03% 622
2021
Q2 		– Sell
-16,192
Closed -$925K – 1173
2021
Q1 		$925K Buy
+16,192
New +$1.08M 0.08% 300
2020
Q4 		– Sell
-40,025
Closed -$1.43M – 1112
2020
Q3 		$1.43M Buy
+40,025
New +$1.21M 0.09% 303
2018
Q3 		– Sell
-10,151
Closed -$155K – 994
2018
Q2 		$155K Buy
+10,151
New +$191K 0.01% 813

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Trexquant Investment's DNLI Position: Q1 2026 in Review

Trexquant Investment sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 209,609 shares — an estimated $3.46M sold.

Trexquant Investment first reported a position in DNLI in Q2 2018 and held it in 14 quarters. The position peaked at $6.25M in Q3 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Trexquant Investment reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Trexquant Investment sold 209,609 Denali Therapeutics shares in Q1 2026, an estimated $3.46M.
  • Trexquant Investment first reported a position in Denali Therapeutics in Q2 2018 and held it in 14 quarters.
  • Trexquant Investment's Denali Therapeutics position peaked at $6.25M in Q3 2025.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.